CHI Announces Mark Bagarazzi, MD, Inovio's CMO to Speak at Upcoming Conference

Today, Inovio Pharmaceuticals reports long-term immune responses from therapeutic cervical dysplasia and cancer DNA vaccine. Mark Bagarazzi, M.D., Chief Medical Officer, will speak at CHI's Clinical Development of Vaccines conference.
 
 
Spread the Word
Listed Under

Tags:
Inovio
Vaccine
Vaccine Conference
Chi
Vaccination
Clinical
Clinical Vaccine
Nih
Cancer Vaccines
Diabetes
Hiv

Industrys:
Biotech
Science
Medical

Location:
Needham - Massachusetts - US

May 10, 2011 - PRLog -- In response to today's news about Inovio Pharmaceuticals:

http://ir.inovio.com/index.php?s=43&item=430

Cambridge Healthtech Institute has confirmed Mark Bagarazzi, M.D., as a speaker at the upcoming Clinical Development of Therapeutic Vaccines conference taking place on August 17-18, 2011 at the Boston Cambridge Marriott Hotel in Cambridge, MA.

Dr. Bagarazzi is will speak on Thursday, August 18 at 10:30 a.m.

This conference is part of ImVacS: The Immunotherapeutics & Vaccine Summit.

For details on Dr. Bagarazzi's presentation and to register, visit http://www.healthtech.com/imt/clv or call 781-972-5400.

Delegates that register by May 13 will save up to $400 off the published rate.

Writers and editors are invited to attend.  To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (http://www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com
End
Source:
Email:***@healthtech.com Email Verified
Phone:781.972.5400
Zip:02494
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Cambridge Healthtech Institute PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share